
    
      Study duration per participant will be approximately 6 months including: 1 day of screening
      and vaccination, 1 or 2 additional visits at Day 6 and Day 30, 2 phone calls and a safety
      follow-up/end of study visit, at Day 8 and Day 180 after vaccine administration,
      respectively.

      Safety assessment includes solicited reactions within 7 days after vaccination, unsolicited
      adverse events (AEs) up to 30 days after vaccination, serious adverse events (SAEs)
      throughout the study.
    
  